ErgoSuture is dedicated to the design, development and commercialization of enhanced suturing devices.

Suturing is a fundamental part of surgery, and our products allow surgeons to effortlessly drive a needle through tissue for use in any situation.

Laparoscopic needle drivers were developed to overcome some of these challenges, but the resulting specialization and learning curve have compounded the challenge. 

SURGEONS NEED A SIMPLE, STRAIGHTFORWARD SOLUTION.

Our premiere product, Drive’N Roll will enable consistent suturing by simplifying the suturing process. 

Drive’N Roll was designed by a surgeon for surgeons.

It’s an intuitive, easy to use and versatile suturing technology that mimics traditional suture devices surgeons are commonly trained with.

AND AT A FRACTION OF THE COST OF COMPETITIVE PRODUCTS.

The ErgoSuture business model and mission was born in 2017,
“Design, develop and commercialize — through strategic partnerships — enhanced suturing devices.” 

To date, we have achieved proof-of-concept for a laparoscopic device: distal end enables surgeon to drive needles of various sizes in both directions and on multiple planes.

EASY TO MANAGE, LESS STRESSFUL FOR THE SURGEON WHEN PASSING THROUGH TISSUES
 

VERY USEFUL FOR GYNECOLOGY SURGEONS WORKING DEEP IN THE PELVIS
 

COULD ALSO BE ADOPTED TO ROBOT-ASSISTED DEVICES
 

ADVANTAGEOUS VERSUS A NEEDLE HOLDER TO WORK IN TIGHT SPACES WITH GREATER FLEXIBILITY

CLAUDE NOGARD, CEO AND CO-FOUNDER | has more than 20 years of global experience in the healthcare industry with pharmaceuticals and vaccines (Merck and Novartis). He is a strategic thinker and has extensive marketing experience, from product development, launch, and management.
 

LUIS ALMODOVAR, CSO AND CO-FOUNDER | is a neurosurgeon and the inventor of Drive’N Roll. He splits his time between his practice in neurosurgical oncology and ErgoSuture research and development.

ERIC HALIOUA, INDEPENDENT DIRECTOR OF THE BOARD | is a serial entrepreneur. He has co-founded five biotechnology and medical device companies. He’s raised more than $100 million over the course of his career and has had numerous successes in the sale and initial public offerings of biotechnology companies. He was the CEO and co-founder of Myosix, which sold to Genzyme/Sanofi in 2002.